NOVEL COMPOSITION FOR TREATMENT OF ESSENTIAL THROMBOCYTHEMIA

摘要

The present invention relates to a pharmaceutical composition free of gastric coating comprising anagrelide HCl, a non-pH dependent polymer and a pharmaceutically acceptable water soluble acid selected from the group of adipic acid, ascorbic acid, citric acid, fumaric acid, malic acid, succinic acid, tartaric acid or a mixture thereof and magnesium stearate, wherein the anagrelide HCl is in the form of particles wherein at least 90% of said particles are smaller than 10 μm in diameter and the amount of the non-pH dependent polymers is 1.5 to 2.5 fold of the anagrelide (w/w), and to the use thereof for the treatment of essential thrombocythemia.